Literature DB >> 30109704

Optical coherence tomography in acute optic neuritis: A population-based study.

Kerstin Soelberg1,2,3,4,5, Svenja Specovius6,7,8,9, Hanna G Zimmermann6,7,8,9, Jakob Grauslund5,10, Jesper J Mehlsen11, Clement Olesen1, Allan S B Neve1, Friedemann Paul6,7,8,9,12, Alexander U Brandt6,7,8,9,13, Nasrin Asgari1,2,3.   

Abstract

OBJECTIVES: To measure early structural damage caused by autoimmune inflammatory optic neuritis (ON) by optical coherence tomography (OCT) in a population-based cohort.
METHODS: In a prospective population-based study over 24 months in Southern Denmark, patients diagnosed with acute ON and without prior diagnosis of a chronic neuroinflammatory disorder were included and examined with OCT, visual evoked potentials (VEP), visual fields, high contrast visual acuity (HCVA), and low contrast letter acuity (LCLA). Structural and functional outcomes were determined at 6-month follow-up based on interocular differences.
RESULTS: The 50 included patients had on average 16.9 μm peripapillary retinal nerve fiber layer loss, 10.6 μm ganglion cell and inner plexiform layer (GCIP) loss, and an average HCVA decrease of 0.22 dec. Based on a linear regression model, average GCIP loss amounted to -0.2 μm per day and started 8 days after onset. OCT outcomes but not VEP correlated well with all visual function measurements at follow-up. Structural and functional damage in 20 patients (40%) diagnosed de novo with multiple sclerosis (MS) and in 2 patients (4%) with positive myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) test did not differ from patients with idiopathic ON.
CONCLUSIONS: Optic neuritis causes substantial retinal damage and vision loss independent of the underlying disease. Our study supports that GCIP damage starts closely to clinical onset. Good structure-function correlations between OCT and vision support the importance of OCT in monitoring acute ON.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  autoimmune diseases; multiple sclerosis; myelin oligodendrocyte glycoprotein autoantibodies; optic neuritis; optical coherence tomography

Mesh:

Year:  2018        PMID: 30109704     DOI: 10.1111/ane.13004

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  9 in total

1.  Visual Outcomes of Plasma Exchange Treatment of Steroid-Refractory Optic Neuritis: A Retrospective Monocentric Analysis.

Authors:  Nic Skorupka; Andrei Miclea; Katarzyna Aleksandra Jalowiec; Christoph Bocksrucker; Nicole Kamber; Andrew Chan; Behrouz Mansouri Taleghani; Robert Hoepner; Anke Salmen
Journal:  Transfus Med Hemother       Date:  2019-11-14       Impact factor: 3.747

Review 2.  Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis.

Authors:  Nadja Borisow; Masahiro Mori; Satoshi Kuwabara; Michael Scheel; Friedemann Paul
Journal:  Front Neurol       Date:  2018-10-23       Impact factor: 4.003

3.  Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?

Authors:  Hadas Stiebel-Kalish; Mark Andrew Hellmann; Michael Mimouni; Friedemann Paul; Omer Bialer; Michael Bach; Itay Lotan
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-05-21

4.  Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) - preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial.

Authors:  Christian Albert; Janine Mikolajczak; Anja Liekfeld; Sophie K Piper; Michael Scheel; Hanna G Zimmermann; Claus Nowak; Jan Dörr; Judith Bellmann-Strobl; Claudia Chien; Alexander U Brandt; Friedemann Paul; Olaf Hoffmann
Journal:  BMC Neurol       Date:  2020-03-03       Impact factor: 2.474

Review 5.  Identification of posterior visual pathway lesions and MRI burden in people with Multiple Sclerosis.

Authors:  Tareef S Daqqaq
Journal:  Neurosciences (Riyadh)       Date:  2021-04       Impact factor: 0.906

6.  Matrine treatment reduces retinal ganglion cell apoptosis in experimental optic neuritis.

Authors:  Jian Kang; Shuqing Liu; Yifan Song; Yaojuan Chu; Mengru Wang; Yamin Shi; Fengyan Zhang; Lin Zhu
Journal:  Sci Rep       Date:  2021-05-04       Impact factor: 4.379

7.  Dynamics of Retinal Vessel Loss After Acute Optic Neuritis in Patients With Relapsing Multiple Sclerosis.

Authors:  Lilian Aly; Christina Noll; Rebecca Wicklein; Elisabeth Wolf; Eva Feodora Romahn; Josphine Wauschkuhn; Sami Hosari; Christian Mardin; Achim Berthele; Bernhard Hemmer; Thomas Korn; Benjamin Knier
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-03-17

8.  Efficacy of Plasma Exchange Treatment for Demyelinating Optic Neuritis Associated with Various Serum Antibodies: A Prospective Cohort Study.

Authors:  Junxia Fu; Yongping Wang; Hongen Li; Huanfen Zhou; Honglu Song; Mingming Sun; Quangang Xu; Shaoying Tan; Shihui Wei
Journal:  Neurol Ther       Date:  2022-04-09

9.  Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO).

Authors:  Alexander U Brandt; Friedemann Paul; Svenja Specovius; Hanna G Zimmermann; Frederike Cosima Oertel; Claudia Chien; Charlotte Bereuter; Lawrence J Cook; Marco Aurélio Lana Peixoto; Mariana Andrade Fontenelle; Ho Jin Kim; Jae-Won Hyun; Su-Kyung Jung; Jacqueline Palace; Adriana Roca-Fernandez; Alejandro Rubio Diaz; Maria Isabel Leite; Srilakshmi M Sharma; Fereshte Ashtari; Rahele Kafieh; Alireza Dehghani; Mohsen Pourazizi; Lekha Pandit; Anitha Dcunha; Orhan Aktas; Marius Ringelstein; Philipp Albrecht; Eugene May; Caryl Tongco; Letizia Leocani; Marco Pisa; Marta Radaelli; Elena H Martinez-Lapiscina; Hadas Stiebel-Kalish; Mark Hellmann; Itay Lotan; Sasitorn Siritho; Jérôme de Seze; Thomas Senger; Joachim Havla; Romain Marignier; Caroline Tilikete; Alvaro Cobo Calvo; Denis Bernardi Bichuetti; Ivan Maynart Tavares; Nasrin Asgari; Kerstin Soelberg; Ayse Altintas; Rengin Yildirim; Uygur Tanriverdi; Anu Jacob; Saif Huda; Zoe Rimler; Allyson Reid; Yang Mao-Draayer; Ibis Soto de Castillo; Michael R Yeaman; Terry J Smith
Journal:  BMJ Open       Date:  2020-10-29       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.